Related Experiment Video

Updated: Aug 21, 2026

Cerebellar Regional Dissection for Molecular Analysis
08:51

Cerebellar Regional Dissection for Molecular Analysis

Published on: December 5, 2020

Cerebellar ataxia in pediatric patients with Langerhans cell histiocytosis

Shinsaku Imashuku1, Shuichi Ishida, Kenichi Koike

  • 1Division of Pediatrics, Kyoto City Hospital and Kyoto City Institute of Health and Environmental Sciences, Kyoto, Japan. shinim95@mbox.kyot-inet.or.jp

Journal of Pediatric Hematology/Oncology
|November 16, 2004
PubMed

Insights

Langerhans cell histiocytosis (LCH) can cause delayed central nervous system (CNS) issues like cerebellar ataxia in children. Early MRI monitoring is crucial for detecting these rare but serious LCH complications.

Area of Science:

  • Pediatric Neurology
  • Neuro-oncology
  • Histiocytosis

Background:

  • Langerhans cell histiocytosis (LCH) is a rare disorder with poorly understood central nervous system (CNS) pathogenetic mechanisms.
  • While diabetes insipidus in LCH is manageable, effective treatments for CNS complications remain elusive.

Observation:

  • Three pediatric cases of LCH presenting with cerebellar ataxia were analyzed.
  • These cases, along with literature review, revealed a median LCH onset at 2.5 years and cerebellar lesion onset at 7 years.
  • Two patients developed diabetes insipidus after initial chemotherapy for multifocal LCH lesions.

Findings:

  • Cerebellar ataxia in LCH patients can manifest with delayed onset, typically between ages 4-8 years, even after initial treatment response.
  • Analysis of combined cases shows a median age of 7 years for cerebellar lesion/ataxia onset.
  • The incidence of cerebellar LCH involvement is low, but delayed CNS disease onset necessitates vigilant follow-up.

Implications:

  • Delayed onset of CNS disease in pediatric LCH patients requires careful long-term monitoring.
  • Brain MRI is recommended for early detection of cerebellar lesions in LCH.
  • Further research is needed to determine therapeutic strategies for preventing CNS disease progression in LCH.

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Encephalitis l: Introduction01:19

Encephalitis l: Introduction

Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...